Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Assets (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Non-Current Assets data on record, last reported at $15.8 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 14.97% year-over-year to $15.8 million; the TTM value through Sep 2025 reached $55.5 million, down 2.33%, while the annual FY2024 figure was $13.3 million, 8.02% down from the prior year.
  • Non-Current Assets reached $15.8 million in Q3 2025 per PLX's latest filing, up from $13.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $15.8 million in Q3 2025 and bottomed at $10.9 million in Q4 2022.
  • Average Non-Current Assets over 5 years is $13.0 million, with a median of $13.0 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: tumbled 51.83% in 2021, then surged 36.55% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $12.0 million in 2021, then dropped by 9.1% to $10.9 million in 2022, then skyrocketed by 32.96% to $14.5 million in 2023, then decreased by 8.02% to $13.3 million in 2024, then grew by 18.16% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $15.8 million in Q3 2025, $13.0 million in Q2 2025, and $13.4 million in Q1 2025.